Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

González-Barca E, Boumendil A, Blaise D, Trněný M, Masszi T, Finel H, Michieli MG, Bittenbring JT, Gritti G, Snowden JA, Bishton M, Bruno B, de Villambrosia SG, Janikova A, Leleu X, Anagnostopoulos A, Poiré X, Crysandt M, Özkurt ZN, Vandenberghe E, Itälä-Remes M, Cahn JY, Jantunen E, Schroyens W, Maertens J, Esquirol A, Dreger P, Montoto S, Sureda A.

Bone Marrow Transplant. 2019 Sep 20. doi: 10.1038/s41409-019-0650-x. [Epub ahead of print]

PMID:
31541205
2.

Frontline management of nodular lymphocyte predominant Hodgkin lymphoma - a retrospective UK multicentre study.

Wilson MR, Bagguley T, Smith A, Roman E, Patmore R, Hanlon K, Leach M, Bishton M, Burton C, McKay P.

Br J Haematol. 2019 Sep;186(6):e214-e217. doi: 10.1111/bjh.16109. Epub 2019 Jul 25. No abstract available.

PMID:
31344253
3.

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.

Barraclough A, Alzahrani M, Ettrup MS, Bishton M, van Vliet C, Farinha P, Gould C, Birch S, Sehn LH, Sovani V, Ward MS, Augustson B, Biccler J, Connors JM, Scott DW, Gandhi MK, Savage KJ, El-Galaly T, Villa D, Cheah CY.

Blood Adv. 2019 Jul 9;3(13):2013-2021. doi: 10.1182/bloodadvances.2019000251.

4.

Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.

Eyre TA, Kirkwood AA, Wolf J, Hildyard C, Mercer C, Plaschkes H, Griffith J, Fields P, Gunawan A, Oliver R, Booth S, Martinez-Calle N, McMillan A, Bishton M, Fox CP, Collins GP, Hatton CSR.

Br J Haematol. 2019 Oct;187(2):185-194. doi: 10.1111/bjh.16070. Epub 2019 Jun 20.

PMID:
31222719
5.

Retraction: The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling.

Mansour M, Haupt S, Chan AL, Godde N, Rizzitelli A, Loi S, Caramia F, Deb S, Takano EA, Bishton M, Johnstone C, Monahan B, Levav-Cohen Y, Jiang YH, Yap AS, Fox S, Bernard O, Anderson R, Haupt Y.

Cancer Res. 2019 Jun 1;79(11):3008. doi: 10.1158/0008-5472.CAN-19-1133. No abstract available.

PMID:
31160311
6.

Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP.

Eyre TA, Martinez-Calle N, Hildyard C, Eyre DW, Plaschkes H, Griffith J, Wolf J, Fields PA, Gunawan A, Oliver R, Booth S, McMillan A, Fox CP, Bishton M, Collins GP, Hatton CSR.

Br J Haematol. 2019 Aug;186(4):e94-e98. doi: 10.1111/bjh.15927. Epub 2019 Apr 24. No abstract available.

PMID:
31020646
7.

A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.

Ng ZY, Bishton M, Ritchie D, Campbell R, Gilbertson M, Hill K, Ratnasingam S, Schwarer A, Manos K, Shorten S, Ng M, Nelson N, Xin L, De Mel Widanalage S, Sunny T, Purtill D, Poon M, Johnston A, Cochrane T, Lee HP, Hapgood G, Tam C, Opat S, Hawkes E, Seymour J, Cheah CY.

Hematol Oncol. 2019 Aug;37(3):253-260. doi: 10.1002/hon.2618. Epub 2019 May 24.

PMID:
30983008
8.

Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma.

Sorigue M, Bishton M, Domingo-Domenech E, McMillan A, Prusila R, García O, Kuusisto M, Condom M, Tapia G, Ribera JM, Kuittinen O, Fox CP, Sancho JM.

Leuk Lymphoma. 2019 Oct;60(10):2524-2531. doi: 10.1080/10428194.2019.1594212. Epub 2019 Apr 3.

PMID:
30942640
9.

Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age.

Eyre TA, Martinez-Calle N, Hildyard C, Eyre DW, Plaschkes H, Griffith J, Wolf J, Fields P, Gunawan A, Oliver R, Djebbari F, Booth S, McMillan A, Fox CP, Bishton MJ, Collins GP, Hatton CSR.

J Intern Med. 2019 Jun;285(6):681-692. doi: 10.1111/joim.12889. Epub 2019 Apr 11.

PMID:
30811713
10.

Complete remission of immunochemotherapy-refractory monomorphic post-transplant lymphoproliferative disorder mediated by endogenous T-cell recovery.

Bishton MJ, Long HM, Dowell AC, Meckiff BJ, Byrne C, Fox CP.

Leuk Lymphoma. 2019 Aug;60(8):2075-2078. doi: 10.1080/10428194.2019.1571203. Epub 2019 Feb 5. No abstract available.

PMID:
30721640
11.

Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis.

Martínez-Calle N, Hartley S, Ahearne M, Kasenda B, Beech A, Knight H, Balotis C, Kennedy B, Wagner S, Dyer MJS, Smith D, McMillan AK, Miall F, Bishton M, Fox CP.

Br J Haematol. 2019 Mar;184(6):957-968. doi: 10.1111/bjh.15722. Epub 2018 Dec 13.

PMID:
30548597
12.

Population-based study of mantle cell lymphoma: Improvements in survival only seen in younger patients.

Joshi K, Hubbard R, Bishton MJ.

Hematol Oncol. 2018 Jan 24. doi: 10.1002/hon.2495. [Epub ahead of print] No abstract available.

PMID:
29363157
13.

Single-center Series of Bone Marrow Biopsy-Defined Large Granular Lymphocyte Leukemia: High Rates of Sustained Response to Oral Methotrexate.

Munir T, Bishton MJ, Carter I, McMillan A, O'Connor S, Sovani V, Haynes AP, Fox CP.

Clin Lymphoma Myeloma Leuk. 2016 Dec;16(12):705-712. doi: 10.1016/j.clml.2016.08.014. Epub 2016 Aug 10.

PMID:
27640075
14.

The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling.

Mansour M, Haupt S, Chan AL, Godde N, Rizzitelli A, Loi S, Caramia F, Deb S, Takano EA, Bishton M, Johnstone C, Monahan B, Levav-Cohen Y, Jiang YH, Yap AS, Fox S, Bernard O, Anderson R, Haupt Y.

Cancer Res. 2016 Jul 15;76(14):4236-48. doi: 10.1158/0008-5472.CAN-15-1553. Epub 2016 May 26. Retraction in: Cancer Res. 2019 Jun 1;79(11):3008.

15.

The role of high-dose chemotherapy and autologous stem cell transplant for treatment-naΪve patients with peripheral T-cell lymphoma: a systematic review of the literature.

Jethwa KD, Bishton MJ, Fox CP.

Br J Haematol. 2017 Aug;178(3):476-479. doi: 10.1111/bjh.14130. Epub 2016 May 5. Review. No abstract available.

PMID:
27146257
16.

Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma.

Reyal Y, Kayani I, Bloor AJC, Fox CP, Chakraverty R, Sjursen AM, Fielding AK, Ben Taylor M, Bishton MJ, Morris EC, Thomson KJ, Russell N, Mackinnon S, Peggs KS.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1234-1241. doi: 10.1016/j.bbmt.2016.03.034. Epub 2016 Apr 14.

17.

Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score? Reply to Adams and Kwee.

Bishton MJ, McMillan AK, Fox CP.

Br J Haematol. 2017 Apr;177(2):320-321. doi: 10.1111/bjh.14050. Epub 2016 Mar 28. No abstract available.

PMID:
27018322
18.

Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.

Bishton MJ, Hughes S, Richardson F, James E, Bessell E, Sovani V, Ganatra R, Haynes AP, McMillan AK, Fox CP.

Br J Haematol. 2016 Jan;172(2):246-54. doi: 10.1111/bjh.13831. Epub 2015 Nov 18.

PMID:
26577576
19.

Era-by-era improvement in survival for elderly patients with Hodgkin lymphoma; outcome data from a large population-based cohort.

Bishton MJ, Hubbard R, Witherall R, Jones SG, Richardson F, James EJ, Sovani V, Bessell EM, Haynes AP, McMillan AK, Fox CP.

Ann Oncol. 2015 Nov;26(11):2356-7. doi: 10.1093/annonc/mdv359. Epub 2015 Sep 15. No abstract available.

PMID:
26374286
20.

EBV-driven relapse of peripheral T-cell lymphoma, masquerading as a post transplant lymphoproliferative disorder following allo-SCT.

Fox CP, Bishton MJ, O'Connor S, Hughes S, Byrne JL, Russell N.

Bone Marrow Transplant. 2014 Jan;49(1):150-2. doi: 10.1038/bmt.2013.125. Epub 2013 Aug 12. No abstract available.

PMID:
23933761
21.

A single-arm, phase II study of the anti-Blys monoclonal antibody belimumab in symptomatic Waldenstrom macroglobulinemia.

Bishton M, Spencer A, Dickinson M, Ritchie D.

Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):575-8. doi: 10.1016/j.clml.2013.04.006. Epub 2013 Jun 15.

PMID:
23773449
22.

Histone deacetylase inhibitors reduce glycoprotein VI expression and platelet responses to collagen related peptide.

Bishton MJ, Gardiner EE, Harrison SJ, Prince HM, Johnstone RW.

Thromb Res. 2013 Jun;131(6):514-20. doi: 10.1016/j.thromres.2013.02.013. Epub 2013 May 2.

PMID:
23642854
23.

A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).

Harrison SJ, Bishton M, Bates SE, Grant S, Piekarz RL, Johnstone RW, Dai Y, Lee B, Araujo ME, Prince HM.

Epigenomics. 2012 Oct;4(5):571-89. doi: 10.2217/epi.12.52.

PMID:
23130838
24.

Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia.

Bishton MJ, Harrison SJ, Martin BP, McLaughlin N, James C, Josefsson EC, Henley KJ, Kile BT, Prince HM, Johnstone RW.

Blood. 2011 Mar 31;117(13):3658-68. doi: 10.1182/blood-2010-11-318055. Epub 2011 Feb 3. Erratum in: Blood. 2015 Jun 11;125(24):3824-5.

PMID:
21292776
25.

MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi).

Burbury KL, Bishton MJ, Johnstone RW, Dickinson MJ, Szer J, Prince HM.

Ann Hematol. 2011 Jul;90(7):847-9. doi: 10.1007/s00277-010-1099-6. Epub 2010 Oct 15. No abstract available.

PMID:
20949272
26.

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies.

Bishton MJ, Johnstone RW, Dickinson M, Harrison S, Prince HM.

Pharmaceuticals (Basel). 2010 Aug 17;3(8):2674-2688. Review.

27.

What is responsible for the recent improvements in outlook for patients with follicular lymphoma?

Bishton MJ, Seymour JF.

Leuk Lymphoma. 2010 Jun;51(6):960-2. doi: 10.3109/10428194.2010.493252. No abstract available.

PMID:
20536343
28.

Light chain deposition disease presenting as massive hepatomegaly.

Nath SV, Peiris M, Bishton MJ, Maxwell E, Prince HM.

Pathology. 2010 Apr;42(3):307-10. doi: 10.3109/00313021003631171. No abstract available.

PMID:
20350234
29.

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.

Dickinson M, Ritchie D, DeAngelo DJ, Spencer A, Ottmann OG, Fischer T, Bhalla KN, Liu A, Parker K, Scott JW, Bishton M, Prince HM.

Br J Haematol. 2009 Oct;147(1):97-101. doi: 10.1111/j.1365-2141.2009.07837.x. Epub 2009 Aug 5.

PMID:
19663825
30.

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors.

Prince HM, Bishton MJ, Johnstone RW.

Future Oncol. 2009 Jun;5(5):601-12. doi: 10.2217/fon.09.36. Review.

PMID:
19519200
31.

Clinical studies of histone deacetylase inhibitors.

Prince HM, Bishton MJ, Harrison SJ.

Clin Cancer Res. 2009 Jun 15;15(12):3958-69. doi: 10.1158/1078-0432.CCR-08-2785. Epub 2009 Jun 9. Review.

32.

Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab.

Bishton MJ, Leahy MF, Hicks RJ, Turner JH, McQuillan AD, Seymour JF.

Ann Oncol. 2008 Sep;19(9):1629-33. doi: 10.1093/annonc/mdn172. Epub 2008 Jun 2.

PMID:
18522934
33.

Claimed association of absolute lymphocyte count with therapeutic efficacy of radio-immunotherapy in patients with indolent lymphoma cannot be verified in an independent data set.

Bishton MJ, Hicks RJ, Prince HM, Ritchie DS, Wolf M, Seymour JF.

Leukemia. 2008 Dec;22(12):2259-60; author reply 2260-1. doi: 10.1038/leu.2008.116. Epub 2008 May 15. No abstract available.

PMID:
18480835
34.

A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy.

Bishton MJ, Hicks RJ, Westerman DA, Prince MH, Wolf M, Seymour JF.

Haematologica. 2008 May;93(5):789-90. doi: 10.3324/haematol.12253. No abstract available.

35.

Histone deacetylase inhibitors in lymphoma and solid malignancies.

Rasheed W, Bishton M, Johnstone RW, Prince HM.

Expert Rev Anticancer Ther. 2008 Mar;8(3):413-32. doi: 10.1586/14737140.8.3.413. Review.

PMID:
18366289
36.

IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma.

Fox CP, McMillan AK, Bishton MJ, Haynes AP, Russell NH.

Br J Haematol. 2008 Apr;141(2):244-8. doi: 10.1111/j.1365-2141.2008.07068.x.

PMID:
18353164
37.

The potential of histone deacetylase inhibitors for the treatment of multiple myeloma.

Prince HM, Bishton M, Harrison S.

Leuk Lymphoma. 2008 Mar;49(3):385-7. doi: 10.1080/10428190801950058.

PMID:
18297514
38.

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.

Bishton M, Kenealy M, Johnstone R, Rasheed W, Prince HM.

Expert Rev Anticancer Ther. 2007 Oct;7(10):1439-49. Review.

PMID:
17944568
39.

Spinal epidural lipomatosis in myeloma.

Liew MS, Bishton MJ, Januszewicz H, Alatakis S, Prince HM.

Leuk Lymphoma. 2007 Oct;48(10):2068-70. No abstract available.

PMID:
17852706
40.

High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myeloma.

Bishton M, Gilyead M, Das Gupta E, Williams C, Russell NH, Byrne JL.

Leuk Res. 2007 Aug;31(8):1063-8. Epub 2007 Feb 26.

PMID:
17324463
42.

Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma.

Bishton MJ, Haynes AP.

Br J Haematol. 2007 Jan;136(1):111-3. Epub 2006 Nov 20.

PMID:
17116129
43.

Opsoclonus myoclonus following allogeneic haematopoietic stem cell transplantation.

Bishton MJ, Das Gupta E, Byrne JL, Russell NH.

Bone Marrow Transplant. 2005 Nov;36(10):923. No abstract available.

PMID:
16113657
44.

The role of granulocyte transfusions in neutropenic patients.

Bishton M, Chopra R.

Br J Haematol. 2004 Dec;127(5):501-8. Review.

PMID:
15566353

Supplemental Content

Loading ...
Support Center